300636 Jiangxi Synergy Pharmaceutical
- 9.99
- -0.05-0.50%
Jiangxi Synergy Pharmaceutical News
Tonghe Pharmaceutical (300636): High-speed release of new products is expected to enter a stage of rapid development
The company's 2023 annual report: In 2023, the company achieved operating income of 722 million yuan, an increase of 0.31%; net profit to mother was 106 million yuan, an increase of 5.28% over the previous year; net profit of non-return to mother was 98 million yuan
Tonghe Pharmaceutical (300636): The inflection point has reached an impressive Q1 performance; new products bring a new cycle
Incident: The company released its 2023 annual report and 2024 quarterly report. The revenue for 2023 was 722 million yuan, up 0.31% year on year, and net profit to mother was 106 million yuan, up 5.28% year on year, after deducting non-net profit
Tonghe Pharmaceutical (300636) 2023 Report and 2024 Quarterly Report Review: 24Q1 showed significant month-on-month improvement, and new production capacity is about to be put into operation
Note: Recently, the company published its 23 annual report and 24 quarterly report. Revenue of $722 million (+0.31%), net profit attributable to mother of $106 million (+5.28%), net profit of non-return to mother of $98 million
Express News | Tonghe Pharmaceutical: Judging from the performance in the first quarter, sales of new products already account for more than half of revenue and will continue to increase in the future
Pacific released a research report on April 26 stating that Tonghe Pharmaceutical (300636.SZ) was given a purchase rating. The main reasons for the rating include: 1) Q1 performance exceeded expectations and profitability was greatly improved; 2) new prod
Pacific released a research report on April 26 stating that Tonghe Pharmaceutical (300636.SZ) was given a purchase rating. The main reasons for the rating include: 1) Q1 performance exceeded expectations and profitability was greatly improved; 2) new product patents are expiring one after another, and it is expected that the standardized market will begin to expand rapidly; 3) production capacity is about to be launched to ensure medium- to long-term performance growth. (Mainichi Keizai Shimbun)
Tonghe Pharmaceutical (300636) 2023 Annual Report and 2024 Quarterly Report Review: Q1 performance exceeds market expectations, new product regulations are about to expand the market
On the evening of April 24, 2024, the company released its 2023 annual report. In 2023, the company achieved operating income of 722 million yuan (YoY +0.31%) and net profit of 106 million yuan (YoY)
Tonghe Pharmaceutical (300636.SZ) reported first-quarter results, net profit of 43.5628 million yuan, an increase of 31.62% over the previous year
Tonghe Pharmaceutical (300636.SZ) released its report for the first quarter of 2024, with revenue of 206 million yuan, a year-on-year decrease of 6.47%. Net profit attributable to shareholders of listed companies was 43.5628 million yuan, an increase of 31.62% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 404.8876 million yuan, an increase of 23.31% over the previous year. Basic earnings per share were $0.1037.
A-share pharmaceutical and medical stocks fluctuated and rebounded
Gelonghui, April 22 | Tonghe Pharmaceutical and Wanfu Biotech rose more than 10%, while shares such as Yahuilong, Sannuo Biotech, Xiangsheng Healthcare, Betta Pharmaceuticals, Hanyu Pharmaceutical, and Eddy Pharmaceuticals rose more than 5%.
Tonghe Pharmaceutical (300636) Follow-up Analysis Report: Deterministic Performance Growth in the Release Cycle for New Varieties Facing Patent Expiration
As we enter the release cycle for new varieties with expired patents, the certainty of performance growth is prominent. Tonghe Pharmaceutical was founded in 2004. After more than ten years of cooperation with customers in Japan and other regulated markets, the company has become one of the API manufacturers with the strictest quality management in China
Pacific Securities: The API industry is in the de-inventory phase or nearing its end, and the 24-year sector is expected to usher in a beta market
The Zhitong Finance App learned that Pacific Securities released a research report saying that in December 2023, production of chemical raw materials by industrial enterprises above the Chinese scale began to resume growth, with a year-on-year increase of 2% and a month-on-month increase of 35%. From January to February 2024, production was 546,000 tons. Although the year-on-year decline was 7.6%, it has already exceeded the same period in 2021 and 2022, continuing the improvement at the end of 2023. As major product patents expire one after another and overseas inventory removal gradually comes to an end, the demand side of the API sector is expected to gradually pick up in 2024, ushering in a beta market. Recommended attention: 1) Continued direction in 2024
Tonghe Pharmaceutical (300636): A large number of expired companies benefiting from patented drugs are expected to bring about an inflection point in performance with the release of new products and production capacity
Starting as a specialty API manufacturer in the high-end market, a reasonable product generation structure will continue to support medium- to long-term development. The company is mainly engaged in R&D, customization and sales of specialty chemical raw materials and intermediates, and patented API intermediates, and has been working hard since its establishment
Tonghe Pharmaceutical (300636.SZ): Approved as a high-tech enterprise
On February 23, Gelonghui | Tonghe Pharmaceutical (300636.SZ) announced that the company was recognized as a high-tech enterprise in 2007 and obtained the “High-tech Enterprise Certificate” issued by the relevant departments, and later passed several reviews and re-accreditation. In 2023, the company carried out the high-tech enterprise re-certification process in accordance with relevant regulations, and recently received the “High-tech Enterprise Certificate” jointly issued by the Jiangxi Provincial Department of Science and Technology, the Jiangxi Provincial Department of Finance, and the Jiangxi Provincial Taxation Bureau of the State Administration of Taxation.
Tonghe Pharmaceutical (300636): Embracing the cliff wave of patents, the first imitation, and the multi-year layout is expected to be implemented one after another
Tonghe Pharmaceutical lays out the API + CMO/CDMO+ formulation business. Under the wave of patent cliffs, the company's product reserves+production capacity release brought performance growth. It was covered for the first time, giving it an “increase in weight” rating. Tonghe Pharmaceutical: Starting from a regulated market, lean type A
Zhitong A Share Sale Restriction and Release List | January 29
According to the Zhitong Finance App, the ban on restricted shares of 21 listed companies was lifted on January 29, with a total market value of about 16.455 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, number of restricted shares, vanadium and titanium shares 000629, share incentives, limited circulation, 4.215,000, Nantian information 000948, share incentives, limited sale and circulation, 50192,000, Kangxin New Materials, 600076, additional A shares, the original shareholders placed and listed 310 million, Electric NetSecurity 002268, 2.1875 million Kamex 002549, additional A shares, corporate placement and listing 7164
Tonghe Pharmaceutical (300636.SZ): The ban on 72.926,200 restricted shares will be lifted on January 29
On January 24, Ge Longhui Pharmaceutical (300636.SZ) announced an indicative announcement on the listing and circulation of restricted shares issued to specific targets. The shares that have been lifted are shares issued by the company to specific targets. The number of shares that have been lifted is 729,261.62 million shares, accounting for 17.23% of the current 423,136,145 shares of the company's total share capital. The stock listing and circulation date for which sales restrictions have been lifted is January 29, 2024 (Monday).
Tonghe Pharmaceutical (300636.SZ): It is likely that in 2024, the company's revenue from new products will surpass mature varieties
Gelonghui January 12 丨 Tonghe Pharmaceutical (300636.SZ) was surveyed by a specific target on January 10, 2024, on “When will the company's revenue from the new product segment surpass mature varieties? What is the outlook for 2024?” The company replied that it is likely that in 2024, the company's revenue from new products will surpass that of mature varieties.
Tonghe Pharmaceutical (300636.SZ): The gross margin of the CDMO business is above 40%
Gelonghui January 12丨Tonghe Pharmaceutical (300636.SZ) was surveyed by a specific target on January 10, 2024, about “How much is the gross margin of the company's CDMO business? What is the outlook for 2024?” The company replied that the gross margin of the company's CDMO business is above 40%; judging from the current market situation, the increase in CDMO business revenue in 2024 is limited.
Tonghe Pharmaceutical (300636.SZ): Gabapentin shipments are expected to increase significantly in 2024 compared to 2023
Gelonghui January 12 丨 Tonghe Pharmaceutical (300636.SZ) was surveyed by a specific target on January 10, 2024, on “How is sales of mature varieties of Gabapentin climbing?” The company replied that there was a marked increase in Gabapentin shipments in the fourth quarter of 2023, but the increase in large orders will have to wait until 2024. It is expected that Gabapentin shipments will increase significantly in 2024 compared to 2023. Our target is 800-1000 tons.
Tonghe Pharmaceutical (300636.SZ): New products have yet to be released in the high-end market in 2023. The growth mainly comes from emerging markets
Gelonghui January 12丨Tonghe Pharmaceutical (300636.SZ) was surveyed by a specific target on January 10, 2024, on “What is the most important source of incremental revenue growth in 2024?” The company replied that the main source of growth is the new product sector. New products have yet to be released in the high-end market in 2023. The growth mainly comes from emerging markets, and sales in emerging markets are greatly affected by customers' ability to pay foreign exchange. It is expected that with the end of the US dollar rate hike, the foreign exchange payment situation in emerging markets will actually improve. In this context, new products achieved sales revenue of 249 million in the first three quarters of 2023, and still
Tonghe Pharmaceutical (300636.SZ): All 4 workshops in the first phase of the second factory area project are in the trial production stage
Gelonghui, January 9 | Tonghe Pharmaceutical (300636.SZ) said at an investor relations event that all 4 workshops in the first phase of the second plant are already in the trial production stage, new products in the high-end market will begin to be released in 2024, and the capacity utilization rate of the first phase of the second plant can reach a high level relatively quickly.
Analysis
Price Target
No Data
